KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Common Equity: 2009-2025

Historic Common Equity for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Sep 2025 value amounting to $7.3 billion.

  • Teva Pharmaceutical Industries' Common Equity rose 13.65% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year increase of 13.65%. This contributed to the annual value of $5.4 billion for FY2024, which is 33.79% down from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' Common Equity stood at $7.3 billion, which was up 6.15% from $6.8 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Common Equity registered a high of $11.5 billion during Q3 2021, and its lowest value of $5.4 billion during Q4 2024.
  • In the last 3 years, Teva Pharmaceutical Industries' Common Equity had a median value of $7.3 billion in 2025 and averaged $7.1 billion.
  • Its Common Equity has fluctuated over the past 5 years, first slumped by 33.79% in 2024, then increased by 13.65% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Common Equity (Quarterly) stood at $11.2 billion in 2021, then declined by 23.53% to $8.6 billion in 2022, then fell by 5.49% to $8.1 billion in 2023, then tumbled by 33.79% to $5.4 billion in 2024, then grew by 13.65% to $7.3 billion in 2025.
  • Its Common Equity was $7.3 billion in Q3 2025, compared to $6.8 billion in Q2 2025 and $6.3 billion in Q1 2025.